CPRX — Catalyst Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $3.85bn
- $3.10bn
- $588.99m
U.S. STOCKS ON THE MOVE-Air Transport Services Group, Dillard's, Precigen
U.S. STOCKS ON THE MOVE-Capri Holdings, Amyris, gold miners
U.S. STOCKS ON THE MOVE-YETI Holdings, Catalyst Pharma, ZimVie
Catalyst Pharma rises after upgrading annual revenue forecast
Catalyst Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Catalyst Pharmaceuticals Q2 Revenue USD 99.6 Million Vs. IBES Estimate USD 91.7 Million
Catalyst Pharmaceuticals Inc expected to post earnings of 42 cents a share - Earnings Preview
Brief: Catalyst Pharma Says CEO Patrick Mcenany Informed Board of Intention To Retire
Brief: Santhera: Exclusive North America License Agreement With Catalyst For Vamorolone
U.S. RESEARCH ROUNDUP-Amazon.com, Fedex, Nike
Brief: Catalyst Pharmaceuticals To License North American Rights To Vamorolone For Duchenne Muscular Dystrophy From Santhera Pharmaceuticals
Brief: Santhera Says Grants Exclusive North America License For Vamorolone To Catalyst Pharmaceuticals In Deal Valued At Up To USD 231 Mln Plus Royalties
Brief: Catalyst Pharmaceuticals Reports Positive Momentum In Second Quarter 2023
Brief: Catalyst Pharmaceuticals Sees FY Revenue USD 375-385 Million
Brief: Catalyst Pharmaceuticals Increases Size Of Board To Eight Members
Brief: Catalyst Pharmaceuticals Appoints Tamar Thompson To Its Board Of Directors
Brief: Catalyst Pharmaceuticals Reports 98% Total Qtrly Revenue Growth Year-Over-Year
Catalyst Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Catalyst Pharmaceuticals Q1 Revenue USD 85.4 Mln